<DOC>
	<DOCNO>NCT02705963</DOCNO>
	<brief_summary>The purpose study evaluate effect trametinib daily pharmacokinetics ( PK ) daily dose oral contraceptive ( OCs ) contain norethindrone ( NE ) ethinyl estradiol ( EE ) female patient solid tumor . The PK trametinib metabolite M5 also assess .</brief_summary>
	<brief_title>A Drug-Drug Interaction Study Assess Effect Trametinib Pharmacokinetics Oral Contraceptive Female Patients With Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Trametinib</mesh_term>
	<mesh_term>Ethinyl Estradiol</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<mesh_term>Polyestradiol phosphate</mesh_term>
	<mesh_term>Contraceptives , Oral</mesh_term>
	<mesh_term>Norethindrone</mesh_term>
	<mesh_term>Norethindrone acetate</mesh_term>
	<mesh_term>Estradiol 3-benzoate</mesh_term>
	<mesh_term>Estradiol 17 beta-cypionate</mesh_term>
	<mesh_term>Estradiol valerate</mesh_term>
	<mesh_term>Contraceptive Agents</mesh_term>
	<mesh_term>Contraceptives , Oral , Combined</mesh_term>
	<criteria>Has histologically cytologically confirm diagnosis solid tumor malignancy ( except exclude malignancy list Exclusion Criteria ) responsive standard therapy ( y ) approve therapy . Meets one follow criterion : Is currently stable regimen oral contraceptive contain 1mg NE 0.035mg EE , Is willing switch regimen oral contraceptive contain 1mg NE 0.035mg EE stable regimen alternate OC , Is willing start regimen oral contraceptive contain 1mg NE 0.035mg EE . Meets one follow criterion : Is postmenopausal , , Women childbearing potential , defined woman physiologically capable become pregnant , unless use highly effective method contraception dose four month stop medication . Has prior treatmentrelated toxicity &gt; Grade 1 ( except alopecia ) time enrolment . Patient must meet following laboratory value screen visit : Absolute Neutrophil Count ≥1.5 x 109/L . Platelets ≥75 x 109/L . Hemoglobin ( Hgb ) ≥9 g/dL . Serum creatinine &lt; 1.5 mg/dL . Total bilirubin ≤1.5 x upper limit normal ( ULN ) ( isolated bilirubin &gt; 1.5x ULN acceptable bilirubin fractionate direct bilirubin &lt; 35 % ) . Aspartate transaminase ( AST ) ≤ 3.0 x ULN , except patient liver metastasis , may include AST ≤5.0 x ULN . Alanine transaminase ( ALT ) ≤ 3.0 x ULN , except patient liver metastasis tumor infiltration , may include ALT ≤5.0 x ULN . Prothrombin time ( PT ) /International normalize ratio ( INR ) Partial thromboplastin time ( PTT ) ≤1.5xULN . Note : patient receive therapeutic anticoagulation agent prior screening permit . Albumin 2.5 g/dL . Patient Eastern Cooperative Oncology Group ( ECOG ) performance status 01 . History current diagnosis cardiac disease indicate significant risk safety patient participate study uncontrolled significant cardiac disease Has major surgery , extensive radiotherapy , anticancer therapy ( e.g. , chemotherapy delay toxicity , biologic therapy , immunotherapy ) within 21 day prior enrolment and/or daily weekly chemotherapy without potential delayed toxicity within 14 day prior enrolment . Prolonged immobilization must resolve prior enrolment . Has know suspect carcinoma exclude administration Oral Contraceptive would contraindicate . Has history another malignancy . Has history interstitial lung disease pneumonitis . Has history RVO . Has history condition would contraindicate administration OC Has symptomatic untreated leptomeningeal , brain metastasis , spinal cord compression . Other protocoldefined Inclusion/Exclusion criterion may apply .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>59 Years</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>